MORRISVILLE, N.C., April 8, 2019 – Myocardial Solutions (MSI) has hired Rafael Rivero, MD as Global Head of Medical Affairs. Rafael’s focus is on expanding utilization and advocacy of MSI’s cardiac diagnostic software, MyoStrain®, in the medical community. Rafael brings over 17 years of experience leading and transforming both medical and operations teams, executing across global health care systems. He brings in a wealth of experience in medical market development, bridging unmet medical needs and achieving standard of care solutions within the biotech and medical device industries. Rafael’s medical background and passion for developing new clinical markets will help make MyoStrain the standard of care cardiac function test available worldwide.
Rafael joins MSI from Mylan, where he served as the Director of Medical Affairs in Pulmonology Specialty. Prior to Mylan, Rafael served as Sr. Executive Director of Medical and Business Operations in Europe, Middle East and Africa (EMEA) for the Cardio Renal Diagnostics portfolio for Ortho Clinical Diagnostics. Rafael led the global integration and operations deployment of two diagnostic biomarkers from startups into the ORTHO business model:
- NephroCheck from Astute Medical for Sepsis and Surgical AKI
- Adrenomedullin (bioADM) from Sphingotec for Acute Heart Failure
Rafael’s experience also includes serving as Europe Sr. Medical Scientist for Gilead Sciences, leading the HIV/AIDS Protease and Integrase Inhibitors portfolio and Sovaldi®, the first Hepatitis C cure. From 2010 – 2012, Rafael was the North America Director of Clinical Development and Training for Stereotaxis, the first Robotic 3D-enabled remote magnetic navigation technology to treat and cure heart arrythmias. Rafael was with Abbott Global R&D Virology from 2006 – 2010 where he led the HIV/AIDS Protease Inhibitors to standard of care and preferred status in treatment guidelines. From 2002 – 2006, Rafael ran USA Medical Affairs activities for the first Molecular Diagnostics technology, PhenoSense GT®, with Monogram Biosciences that became global standard of care and guidelines preferred for the management of HIV medicine.
Rafael received his MD at the Superior School of Medicine in Cuba in 1992 and his USMLE in 1995 in Internal Medicine. Rafael also holds a Master’s in Clinical Virology from Universidad del Rey Juan Carlos, Madrid, SP and various Mental Health and Infectious Disease clinical training certifications.
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.